Callitas Theraputics Inc., a wholly owned subsidiary of M Pharmaceutial Inc.

admin

About admin

This author has not yet filled in any details.
So far admin has created 50 blog entries.

M Pharmaceutical USA Announces a Change of Name to Callitas Therapeutics

2017-07-31T17:31:40+00:00

CINCINNATI, OH, USA (August 1, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB:MPHMF, FWB: T3F2) (“M Pharma”), announces today that to better align with its expertise in the healthcare field, it is changing the name and branding of its wholly owned subsidiary MPharmaceutical USA branding to Callitas Therapeutics Inc. The name of the parent [...]

M Pharmaceutical USA Announces a Change of Name to Callitas Therapeutics 2017-07-31T17:31:40+00:00

M Pharmaceutical Inc. Plans to Submit Extrinsa™ Pind Meeting Request Letter and Package to US FDA

2017-07-31T08:03:45+00:00

CINCINNATI, OH, USA (July 18, 2017) -- M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “M Pharma”), a clinical-stage company developing innovative technologies for weight management and female health and wellness announced today that it has taken important steps to draft and file a Pre Investigational New Drug (PIND) Meeting [...]

M Pharmaceutical Inc. Plans to Submit Extrinsa™ Pind Meeting Request Letter and Package to US FDA 2017-07-31T08:03:45+00:00

M Pharmaceutical Inc. Provides Update on FDA Cleared OTC Product, ToConceive

2017-07-31T07:55:18+00:00

CINCINNATI, OH, USA (July 11, 2017) -- M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “M Pharma”), a clinical-stage company developing innovative technologies for weight management and female health and wellness announced today that it has taken important steps to release the innovative, FDA-cleared OTC product, ToConceive, to the North American [...]

M Pharmaceutical Inc. Provides Update on FDA Cleared OTC Product, ToConceive 2017-07-31T07:55:18+00:00

M Pharmaceutical Reforecasts 2017 and 2018 Revenues Upward

2017-07-31T07:52:57+00:00

CINCINNATI, OH, USA (July 7, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or “M Pharma”), a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it has re-forecasted it’s 2017 third & fourth quarter revenues to reflect increases in current order [...]

M Pharmaceutical Reforecasts 2017 and 2018 Revenues Upward 2017-07-31T07:52:57+00:00

M Pharmaceutical In-licenses Novel Pediatric Orphan Drug To Their Pipeline, With Possible Priority Review Voucher Award

2017-07-31T07:52:05+00:00

CINCINNATI, OH, USA (July 5, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or “M Pharma”), a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it has in-licensed a novel drug product that should qualify as an Orphan Drug under the [...]

M Pharmaceutical In-licenses Novel Pediatric Orphan Drug To Their Pipeline, With Possible Priority Review Voucher Award 2017-07-31T07:52:05+00:00

M Pharmaceutical To Partner On Developing Joint Venture Strategy For Re-Formulated Orlistat Weight Loss Drug C-103

2017-07-31T07:49:56+00:00

CINCINNATI, OH, USA (June 29, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or “M Pharma”), a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it will be pursuing a Joint Venture or Strategic Alliance for the development of its C-103 [...]

M Pharmaceutical To Partner On Developing Joint Venture Strategy For Re-Formulated Orlistat Weight Loss Drug C-103 2017-07-31T07:49:56+00:00

M Pharmaceutical Inc. Announces Extension of Warrants

2017-07-31T07:48:20+00:00

CINCINNATI, OHIO (June 28, 2017) - M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or “M Pharma”), announced today that it has, in respect to  57,838,619 warrants  exercisable at $0,05 per share expiring on June 27 and June 30, 2017, extended the expiry date on these warrants to August 15, 2017. Proceeds from [...]

M Pharmaceutical Inc. Announces Extension of Warrants 2017-07-31T07:48:20+00:00

M Pharmaceutical Inc. Appoints New Chief Financial Officer

2017-06-30T10:21:12+00:00

Cincinnati, Ohio (June 8, 2017) M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB:T3F2 ), (the "Company" or “M Pharma”), today announced that Gary Stephens is joining this global healthcare company as its new Chief Financial Officer (CFO), effective Immediately. Mr. Stephens brings with him an extensive background in corporate finance, treasury planning and analysis, strategic [...]

M Pharmaceutical Inc. Appoints New Chief Financial Officer 2017-06-30T10:21:12+00:00

M Pharmaceutical Inc. Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction

2017-06-30T10:22:33+00:00

Cincinnati, Ohio (June 6, 2017) M Pharmaceutical Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the "Company" or “M Pharma”), is pleased to announce that it has recently received official USPTO “Notice Of Allowance” for the US Trademark of EXTRINSA the Company’s solutionfor Female Sexual Dysfunction (FSD). “We are excited to receive this additional USPTO trademark protection [...]

M Pharmaceutical Inc. Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction 2017-06-30T10:22:33+00:00

M Pharmaceutical Inc. Engages Camargo Pharmaceutical Services To Develop Regulatory Strategy For Recently Patented Extrinsa For the Treatment of Female Sexual Dysfunction

2017-06-30T10:23:32+00:00

Cincinnati, Ohio (June 2, 2017) M Pharmaceutical Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the "Company" or “M Pharma”), is pleased to announce that it has engaged  Camargo Pharmaceutical Services, in order to help advance a drug development strategy for the Company’s recently patented Extrinsa product for Female Sexual Dysfunction (FSD). Known for their experience and [...]

M Pharmaceutical Inc. Engages Camargo Pharmaceutical Services To Develop Regulatory Strategy For Recently Patented Extrinsa For the Treatment of Female Sexual Dysfunction 2017-06-30T10:23:32+00:00